Hong Kong-listed Innovent Biologics Inc. is considering a licensing partnership to develop a cancer drug that's showing promise in treating several types of tumor, according to people familiar with the situation. The Suzhou, Jiangsu province-based firm is working with an adviser to gauge interest from global pharmaceutical companies in its IBI363 drug, the people said, asking not to be identified discussing a private matter. An agreement could secure Innovent an upfront payment as well as others later on if the drug passes key milestones in development and commercialization, the people said.